Fisher DA, Saoud L, Lich KH, et al. - Based on real‐world data for patients with positive colorectal cancer (CRC) screening stool‐tests, lower adenoma detection rates are demonstrated when endoscopists are blinded to the stool‐test results. This suggests the possibility of lower adenoma sensitivity for screening colonoscopy than for follow‐up to a known positive stool‐based test. Researchers here used the Colorectal Cancer and Adenoma Incidence and Mortality Microsimulation Model (CRC‐AIM) to examine how the screening outcomes are affected when assuming different adenoma sensitivity between screening and combined follow‐up/surveillance colonoscopies. Colonoscopy every 10 years, triennial multitarget stool DNA (mt‐sDNA), or annual fecal immunochemical test (FIT) from 50 to 75 years were included in modeled screening strategies. They reported outcomes per 1,000 individuals without diagnosed CRC at age 40. As the disparities in adenoma sensitivity for screening vs follow‐up/surveillance colonoscopies became greater, life‐years gained (LYG) and reductions in CRC‐related incidence and mortality vs no screening raised for mt‐sDNA and FIT and reduced for screening colonoscopy. Per findings, the potential benefits of stool‐based screening strategies are underestimated when identical adenoma sensitivities are assumed for screening and follow‐up/surveillance colonoscopies.